precisionmedicineonline1d
Boehringer Ingelheim Kicks Off Inhaled Cystic Fibrosis Gene Therapy Phase I/II Trial With Partners
Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.
Contract Pharma1d
Eleva Appoints New Chief Medical Officer
Eleva, a pioneer in unlocking difficult-to-produce biologics, has appointed Dr. Martin Bauer, MD, as its new Chief Medical ...
Contract Pharma1d
Boehringer Ingelheim Names Brian Hilberdink as President, U.S. Human Pharma
Boehringer Ingelheim Pharmaceuticals Inc. has appointed Brian Hilberdink as President, U.S. Human Pharma.
Oxford Biomedica to support Boehringer Ingelheim’s LENTICLAIR 1 trial
OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...